Business
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Etalanetug is designed to bind to the microtubule-binding region (MTBR) of tau protein and prevent the seeding and propagation of tau pathology.
About this update from Eisai Co., Ltd.
[{"type":"text","content":"Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase Ib/II study","length":153,"tagName":"p","attribs":{}},{"type":"text","content":"TOKYO, Dec. 1, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Etalanetug is designed to bind to the microtubule-binding region (MTBR) of tau protein and prevent the seeding and propagation of tau pathology.","length":412,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Eisai Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Eisai Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":270,"url":"https://media.zenfs.com/en/prnewswire.com/700c877d19b6c71682541aaa54eb34cb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9Joz3h2FdUIAcnZzvGHF3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/700c877d19b6c71682541aaa54eb34cb","width":400,"height":270}},"href":"https://mma.prnewswire.com/media/2704698/Eisai_Inc_Logo_New.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Anti-tau therapeutic antibody, etalanetug, reduces the novel biomarker plasma eMTBR-tau243 in patients with DIAD (Presentation: December 1, 4:35 PM PT)","length":161,"tagName":"p","attribs":{}},{"type":"text","content":"This presentation is based on the Phase Ib/II study (E2814-103) conducted in individuals (n=7) with dominantly inherited Alzheimer's disease (DIAD)*. In this study, as previously reported, tau aggregates in the brains of individuals (n=3) were measured using tau PET, and the results showed that the observed tau PET signals were stabilized or trended toward decrease following administration of etalanetug, suggesting that etalanetug inhibited tau propagation and suppressed or reduced the accumulation of tau aggregates in brains.1","length":537,"tagName":"p"},{"type":"text","content":"The study evaluated eMTBR-tau243 as a specific biomarker of tau pathology progression and measured changes in cerebrospinal fluid (CSF) and plasma.","length":147,"tagName":"p"},{"type":"text","content":"MTBR-tau243 is a CS...